ATE311880T1 - Carbonische anhydrase inhibitor zur steigerung des sauerstoffdrucks im sehnerv und retina - Google Patents

Carbonische anhydrase inhibitor zur steigerung des sauerstoffdrucks im sehnerv und retina

Info

Publication number
ATE311880T1
ATE311880T1 AT99904804T AT99904804T ATE311880T1 AT E311880 T1 ATE311880 T1 AT E311880T1 AT 99904804 T AT99904804 T AT 99904804T AT 99904804 T AT99904804 T AT 99904804T AT E311880 T1 ATE311880 T1 AT E311880T1
Authority
AT
Austria
Prior art keywords
carbonic anhydrase
retina
oxygen pressure
anhydrase inhibitor
increase oxygen
Prior art date
Application number
AT99904804T
Other languages
English (en)
Inventor
Einar Stefansson
Jens Dollerup
Kurt Bang
Original Assignee
Einar Stefansson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809787.6A external-priority patent/GB9809787D0/en
Application filed by Einar Stefansson filed Critical Einar Stefansson
Application granted granted Critical
Publication of ATE311880T1 publication Critical patent/ATE311880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT99904804T 1998-01-23 1999-01-21 Carbonische anhydrase inhibitor zur steigerung des sauerstoffdrucks im sehnerv und retina ATE311880T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7236098P 1998-01-23 1998-01-23
GBGB9809787.6A GB9809787D0 (en) 1998-05-07 1998-05-07 Method for increasing oxygen tension in the optic nerve and retina
PCT/EP1999/000409 WO1999037292A2 (en) 1998-01-23 1999-01-21 Carbonic anhydrase inhibitor for increasing oxygen tension in the optic nerve and retina

Publications (1)

Publication Number Publication Date
ATE311880T1 true ATE311880T1 (de) 2005-12-15

Family

ID=26313618

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99904804T ATE311880T1 (de) 1998-01-23 1999-01-21 Carbonische anhydrase inhibitor zur steigerung des sauerstoffdrucks im sehnerv und retina

Country Status (7)

Country Link
EP (1) EP1049466B1 (de)
JP (1) JP2002501017A (de)
AT (1) ATE311880T1 (de)
AU (1) AU746893B2 (de)
CA (1) CA2317121A1 (de)
DE (1) DE69928771T2 (de)
WO (1) WO1999037292A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939511B2 (en) 2004-09-28 2011-05-10 Senju Pharmaceutical Co., Ltd. Ophthalmic composition containing xanthan gum and amino acid
JP4872076B2 (ja) * 2005-09-15 2012-02-08 国立大学法人 長崎大学 硝子体可視化剤
CN101405009B (zh) 2006-03-23 2011-04-13 千寿制药株式会社 包含黄原胶和葡萄糖的眼科组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3871596T3 (de) * 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
EP0509753A1 (de) * 1991-04-18 1992-10-21 Merck & Co. Inc. Semisynthetische immunosuppressive Macrolide
WO1993016701A2 (en) * 1992-02-21 1993-09-02 Alcon Laboratories, Inc. Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
US5789435A (en) * 1995-05-22 1998-08-04 Advanced Research And Technology Institute Method to increase retinal and optical nerve head blood flow velocity in order to preserve sight

Also Published As

Publication number Publication date
WO1999037292A3 (en) 1999-10-07
JP2002501017A (ja) 2002-01-15
EP1049466A2 (de) 2000-11-08
CA2317121A1 (en) 1999-07-29
DE69928771T2 (de) 2006-09-07
AU746893B2 (en) 2002-05-02
WO1999037292A2 (en) 1999-07-29
AU2519099A (en) 1999-08-09
DE69928771D1 (de) 2006-01-12
EP1049466B1 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
BRPI0406880A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de inibidores de anidrase carbÈnicos
MXPA02009327A (es) Lente de contacto que tiene un perfil de espesor horizontal uniforme.
WO2003024386A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
NO20004550L (no) Enzyminhibitorer
AU7610696A (en) Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
DK1039895T3 (da) Anvendelse af 3-benzoylphenyleddikesyrer, estere eller amider til behandling af GLC1A-glaukom
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ZA200000494B (en) Protective eyewear.
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
NZ308016A (en) use of a carbonic anhydrase inhibitor applied topically to increase retinal blood flow
FR2754712B1 (fr) Compositions ophtalmiques
ATE311880T1 (de) Carbonische anhydrase inhibitor zur steigerung des sauerstoffdrucks im sehnerv und retina
MXPA98006961A (es) Tratamiento de edema macular.
WO2002078681A3 (en) Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
MXPA03001160A (es) Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico.
ATE269705T1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
UA66757C2 (en) Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
EP0373590A3 (de) Vorläufermedikamente von 3,4-Hydroxy-benzoyl-oxypropanolaminen
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
DE60310212D1 (de) Verwendung eines wasserstoffperoxid produzierenden enzyms zur behandlung von otitis media
DK1251826T3 (da) Diclofenamidsuspensionsgel
MY208609A (en) Ws12-releasing contact lens
ATE270883T1 (de) Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck
UA39717A (uk) Спосіб хірургічного лікування первинної глаукоми
UA39527A (uk) Спосіб лікування опіку очей

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties